Tirzepatide vs semaglutide
Tirzepatide (Zepbound) and semaglutide (Wegovy), side by side.
The form
Two weekly injection options
The routine
A weekly routine for the injections compared here.
The evidence
A direct comparison in a human trial.
The study comparison does not decide which medicine fits an individual.
On this page
A linked source is not a clinical endorsement. How we handle review and corrections.
Side by side
| Tirzepatide (Zepbound) | Semaglutide (Wegovy) | |
|---|---|---|
| How it works | Acts on GLP-1 and GIP receptors | Acts on the GLP-1 receptor |
| Forms | Weekly injection | Weekly injection or daily pill |
| Average weight loss in SURMOUNT-5 | About 20% | About 14% |
| Also approved for | Sleep apnea; type 2 diabetes as Mounjaro | Lowering heart attack and stroke risk; type 2 diabetes as Ozempic |
Side effects
Both cause the same family of side effects, mostly nausea, constipation and diarrhea while the dose rises. In SURMOUNT-5 the rates were broadly similar. A slow schedule matters more than which drug you pick.
How we choose
- If the goal is the most weight loss, we usually start with tirzepatide.
- If you'd rather not inject, the Wegovy pill or Foundayo.
- The exact medication price and the ongoing self-pay total are part of the decision.
- If you're already doing well on one, there's rarely a reason to switch.
Questions people ask
Can I switch from Wegovy to Zepbound?
Yes. We'll pick a starting dose based on where you are and how you tolerated semaglutide.
Which one has fewer side effects?
In the head-to-head trial, neither stood out. Individual people react differently, which is one reason we check in every month.
Sources
- Research publicationTirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) New England Journal of Medicine, 2025
- Research publicationTirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) New England Journal of Medicine, 2022
- Research publicationOnce-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) New England Journal of Medicine, 2021
- Manufacturer informationTirzepatide (Zepbound) prescribing information Eli Lilly, Prescribing information checked October 6, 2026
- Secondary sourceSemaglutide (Wegovy) prescribing information Novo Nordisk, Prescribing information checked October 6, 2026
Good days ahead.
Join the opening list for appointment updates.